Brandon Atienza, Author at Precision Medicine Group

Conference: Gene Therapy for Rare Disorders, 2023

Brandon Atienza2023-03-21T11:25:55-04:00Cell & Gene Therapy, Events, Thought Leadership|

Precision will be at this year’s Gene Therapy for Rare Disorders on March 20-23, 2023, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for gene therapies.

Speaking Engagements
Detailed descriptions for each speaking engagement are included below.

Precision ADVANCE will have a plenary speaking position on March 21, 2023, 8:30 – 9:00 am.
Project Farma will be facilitating a plenary panel discussion ” Current Trends in Technical Operations for Rare Disorders” on March 21, 2023, 10:45 – 11:15 am.
Project Farma’s Tony Khoury (EVP, Project Farma) will be joining the Manufacturing track panel discussion, “Capacity versus Capability – Moving Towards Innovative Manufacturing Processes,” on March 21, 2023, 11:15 – 11:45 am.
Precision ADVANCE will hold a drinks reception on March 21, 2023, at 6:10 pm in the Grand & Liberty Ballroom.

Connect with our Advanced Therapy experts

Visit us at booth 13 in the exhibition area
Schedule in-person or virtual meetings by clicking here: https://bit.ly/precisionmedicinegrp
Attend our ADVANCE-sponsored Drinks Reception on March 21, 2023, at 6:10 PM ET

(more…)

On-Demand: Let’s Talk: Moving CGTx Clinical Development Forward in 2023

Brandon Atienza2023-03-09T12:12:56-05:00Cell & Gene Therapy, Events|

Sponsored by Precision ADVANCE, this Endpoints webinar will convene leading advanced therapy experts to discuss the future of CGTx clinical development. This discussion will be moderated by Teresa Pokladowski: Regional VP, Clinical Business Solutions (Precision for Medicine), and include insights from Kinnari Patel: President & COO (Rocket Pharmaceuticals), Suma Krishnan: Founder & President (Kystal Biotech), Dawn Buchanan: VP Clinical Operations (AffyImmune), and Ramona Repaczki-Jones: Executive Director, Commercial Treatment Center Operations, Cell Therapy (lovance Biotherapeutics, Inc).

(more…)

White Paper: What’s Next for Cell and Gene Therapies in 2023 and Beyond

Brandon Atienza2023-02-10T15:51:26-05:00Cell & Gene Therapy, Thought Leadership|

The cell and gene therapy (CGTx) sector has flourished in recent years due to continued investor confidence. However, the present downturn in public markets has negatively affected that confidence, raising questions about the sector’s prospects for 2023 and beyond.

This white paper is based on a panel discussion at the Cell & Gene Meeting on the Mesa (October 11, 2022), sponsored by Precision ADVANCE, focusing on the future of advanced therapies. The panel included insights from the following industry leaders:

Anshul Mangal: President (Project Farma & Precision ADVANCE)
Stewart Abbot: Chief Scientific Officer (Turnstone Biologics)
Laura Lande-Diner: Chief Business Officer (Satellite Bio)
Robert Peters: Chief Scientific Officer (Ensoma)
Deborah Phippard: Chief Scientific Officer (Precision For Medicine)

(more…)

White Paper: State of the Union for Advanced Medicines

Brandon Atienza2023-02-13T11:09:46-05:00Cell & Gene Therapy, Thought Leadership|

The cell and gene therapy (CGTx) sector has flourished over the last 2 to 5 years due to continued investor confidence. However, the recent downturn in public markets has undermined that confidence.

This white paper is based on a panel discussion, sponsored by Precision ADVANCE, featuring insights from diverse industry perspectives on the current state of the CGTx sector; the investment landscape; scientific and technical advances; progress in drug development, manufacturing, regulatory, pricing, and reimbursement; and expected key trends in 2023 and beyond. Hosted by Endpoints News, the panel included insights from the following industry leaders:

Anshul Mangal: President (Project Farma & Precision ADVANCE)
Dave Greenwald: Vice President of Business Development (Deerfield Management)
Rajul Jain: Managing Director (Vida Ventures)
Joseph LaBarge: Chief Executive Officer (Apertura Gene Therapy)
Adrian Woolfson: Executive Chairman, President and Co-Founder (Replay Bio)
Phil Cyr: Executive Vice President (Precision Value & Health)

(more…)

On-Demand: The Hitchhiker’s Guide to CGTx in 2023

Brandon Atienza2023-01-30T14:52:17-05:00Cell & Gene Therapy, Events|

Cell & gene therapy advancement has increased at an immense rate over the past decade. With the right tools and guidance, patients can receive new forms of treatments. Staying up to date with progress in the field is as important as ever with the constant strive to improve technology, especially in areas like regulatory pathways, novel technologies, and CMC and manufacturing trends.

Sponsored by Precision ADVANCE, this Life Science Connect webinar will convene leading advanced therapy experts to discuss innovation and expectations for advanced therapies in 2023. This discussion will be moderated by Andy Kinley (VP of Innovation & Clinical Science, Precision for Medicine), and include insights from Peter Andersen (CSO, Vita Therapeutics), Deb Phippard (CSO, Precision for Medicine), Palani Palaniappan (CTO, Flagship Pioneering), Phil Cyr (SVP, Precision Value & Health), and Charlie Harper (VP, Project Farma).

(more…)

Article: Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts

Brandon Atienza2022-12-14T10:08:30-05:00Cell & Gene Therapy|

Since the early 2000s, early economic models have been used by many developers as a best practice to maximize development through clinical trial design and commercial success. Early economic models are similar to HTA models in that they assess the direct and indirect costs and consequences of using a new therapy. Based off experience, early health economic models have been particularly useful in three major areas.

Assessing commercial viability
Developing clinical trial design and evidence-generation strategy
Planning for launch preparedness

Ivar Jensen (VP, Precisionheor) is joined by Phil Cyr (SVP, Precision Value & Health) to provide insight on this in “Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts“.

(more…)

On-Demand: State of the Union for Advanced Medicines

Brandon Atienza2022-12-05T15:00:44-05:00Cell & Gene Therapy|

Regenerative medicines are evolving at breakneck speed—and every advance has far-reaching implications. To be effective in CGTx development, you also need to understand the current investment landscape, new and exciting technologies, and the latest progress in drug development, manufacturing, regulatory, and reimbursement.

Sponsored by Precision ADVANCE, this Endpoints webinar with convene leading advanced therapy experts to discuss how to be effective in CGTx development. This discussion will be moderated by Anshul Mangal (President, Project Farma & Precision ADVANCE), and include insights from Phil Cyr (EVP, Precision Value & Health), David Greenwald (VP of Business Development, Deerfield Management), Rajul Jain (Managing Director, Vida Ventures), Joseph La Barge (CEO, Apertura Gene Therapy), and Adrian Woolfson (Executive Chairman, President & Co-Founder, Replay Bio).

(more…)

On-Demand: Gene Therapy Roundup—What to know now from the lab to the FDA

Brandon Atienza2022-11-02T15:59:47-04:00Cell & Gene Therapy, Events|

Gene therapy continues to evolve rapidly – from the science to the regulatory requirements. To give you a greater perspective on recent developments, this panel discussion brings together gene therapy experts across assay development, regulatory submissions, and clinical trial strategy who will share observations from the front lines on a multitude of gene therapy and rare disease projects.

(more…)

About Brandon Atienza